Press release
Synovial Sarcoma Therapeutics – Pipeline Analysis 2019 | Top Players are Eli Lilly and Company, GSK, Advenchen Laboratories, LLC, Epizyme, Immunocore, Immune Design, Adaptimmune
Synovial sarcoma is a soft-tissue sarcoma, which is divided into four stages (I, II, III, and IV) depending on the size of tumor. The growth of the tumor tends to cause numbness and pain in joints when it presses against nerves. The translocation between chromosomes X and 18 is expected to be responsible for causing this disorder. The disease can be diagnosed by genetic testing and diagnostic imagining to confirm the presence of tumors and somatic mutations.
Download the sample pages of report at: https://www.pharmaproff.com/request-sample/1251
There are three commonly used regimes for the treatment of the disease, such as surgery, radiation therapy, and chemotherapy. Among these, surgery is the most favorable treatment option for synovial sarcoma. There are no approved drugs for the primary treatment of synovial sarcoma; however, few drugs including Lartruvo (Eli Lilly and Company) and Votrient (GlaxoSmithKline plc.) are indicated for the treatment of the disease.
According to the research findings, majority of pipeline drug candidates are being developed for oral administration. It has been observed that the oral route of medication is convenient, available in delayed or rapid release formulation, less risk of systemic infections, and inexpensive in nature, and also provides improved patient’s compliance.
Get the detailed analysis at: https://www.pharmaproff.com/report/synovial-sarcoma-therapeutics-pipeline-analysis
Designation Grants by Regulatory Bodies to Accelerate the Development Process of Synovial sarcoma Therapeutics
Lavruto of GlaxoSmithKline plc was granted Orphan Drug Designation for the treatment of soft-tissue sarcoma, including synovial sarcoma in 2014 and the drug was approved for marketing in 2016. Moreover, in July 2016, Adaptimmune Therapeutics plc’s SPEAR T-cell therapy was granted Orphan Drug Designation by European Commission for the treatment of soft-tissue sarcoma.
Companies that are involved in developing therapeutics for synovial sarcoma have shown active involvement in strategic collaborations to boost the development of their candidates for synovial sarcoma. For instance, in 2015, Epizyme Inc. and Eisai entered into a strategic collaboration to co-develop and market tazemetostat.
Make enquiry before purchase at: https://www.pharmaproff.com/enquiry/1251
Global Market of Synovial Sarcoma Therapeutics is Expected to Increase Statistically in the next 10 years
Lartruvo (Eli Lilly and Company) and Votrient (GlaxoSmithKline plc.) are some of the drugs being used for the treatment of synovial sarcoma and with the emergence of late- and mid-stage pipeline products in the market, the overall synovial sarcoma therapeutics market is expected to grow significantly in the upcoming years.
Takara Bio Inc., GlaxoSmithKline plc, Advenchen Laboratories LLC, Epizyme Inc., Immunocore Ltd., Immune Design Corp., and Adaptimmune Limited are some of the key players involved in the development of drugs indicated for the treatment of synovial sarcoma.
Synovial Sarcoma Therapeutics Pipeline Analysis
• By Phase
• By Molecule Type
• By Route of Administration
• By Company
The report comprises detailed pipeline analysis of therapeutics being developed for the treatment of synovial sarcoma. Comprehensive insights on the pipeline products have been provided, with special focus on strategic developments of key players, information on drug licensing, designations, financing, and grants, technological advancements, patents, and upcoming conferences. In addition, the report highlights the winning strategies of companies involved in the synovial sarcoma therapeutics development. Detailed regulatory approval procedures in the U.S., Europe, and Japan are also provided in this report. Furthermore, the report contains competitive analysis and extensive information on monotherapies, combination therapies, targets and mechanisms of action, and drug origin with respect to synovial sarcoma.
Contact:
Pharma Proff
Toll-free: +1-888-778-7886 (USA/Canada)
International: +1-347-960-6455
Email: enquiry@pharmaproff.com
Web: https://www.pharmaproff.com
About Us:
Pharma Proff, is a frontline market intelligence and consulting solutions provider catering to the information and data needs of burgeoning sectors across the world, including pharmaceutical and healthcare. With meticulously curated research reports on the industry landscape, we empower companies in the healthcare and pharmaceutical sectors to make informed business decisions and base their marketing strategies with astuteness.
Download the sample pages of report at: https://www.pharmaproff.com/request-sample/1251
There are three commonly used regimes for the treatment of the disease, such as surgery, radiation therapy, and chemotherapy. Among these, surgery is the most favorable treatment option for synovial sarcoma. There are no approved drugs for the primary treatment of synovial sarcoma; however, few drugs including Lartruvo (Eli Lilly and Company) and Votrient (GlaxoSmithKline plc.) are indicated for the treatment of the disease.
According to the research findings, majority of pipeline drug candidates are being developed for oral administration. It has been observed that the oral route of medication is convenient, available in delayed or rapid release formulation, less risk of systemic infections, and inexpensive in nature, and also provides improved patient’s compliance.
Get the detailed analysis at: https://www.pharmaproff.com/report/synovial-sarcoma-therapeutics-pipeline-analysis
Designation Grants by Regulatory Bodies to Accelerate the Development Process of Synovial sarcoma Therapeutics
Lavruto of GlaxoSmithKline plc was granted Orphan Drug Designation for the treatment of soft-tissue sarcoma, including synovial sarcoma in 2014 and the drug was approved for marketing in 2016. Moreover, in July 2016, Adaptimmune Therapeutics plc’s SPEAR T-cell therapy was granted Orphan Drug Designation by European Commission for the treatment of soft-tissue sarcoma.
Companies that are involved in developing therapeutics for synovial sarcoma have shown active involvement in strategic collaborations to boost the development of their candidates for synovial sarcoma. For instance, in 2015, Epizyme Inc. and Eisai entered into a strategic collaboration to co-develop and market tazemetostat.
Make enquiry before purchase at: https://www.pharmaproff.com/enquiry/1251
Global Market of Synovial Sarcoma Therapeutics is Expected to Increase Statistically in the next 10 years
Lartruvo (Eli Lilly and Company) and Votrient (GlaxoSmithKline plc.) are some of the drugs being used for the treatment of synovial sarcoma and with the emergence of late- and mid-stage pipeline products in the market, the overall synovial sarcoma therapeutics market is expected to grow significantly in the upcoming years.
Takara Bio Inc., GlaxoSmithKline plc, Advenchen Laboratories LLC, Epizyme Inc., Immunocore Ltd., Immune Design Corp., and Adaptimmune Limited are some of the key players involved in the development of drugs indicated for the treatment of synovial sarcoma.
Synovial Sarcoma Therapeutics Pipeline Analysis
• By Phase
• By Molecule Type
• By Route of Administration
• By Company
The report comprises detailed pipeline analysis of therapeutics being developed for the treatment of synovial sarcoma. Comprehensive insights on the pipeline products have been provided, with special focus on strategic developments of key players, information on drug licensing, designations, financing, and grants, technological advancements, patents, and upcoming conferences. In addition, the report highlights the winning strategies of companies involved in the synovial sarcoma therapeutics development. Detailed regulatory approval procedures in the U.S., Europe, and Japan are also provided in this report. Furthermore, the report contains competitive analysis and extensive information on monotherapies, combination therapies, targets and mechanisms of action, and drug origin with respect to synovial sarcoma.
Contact:
Pharma Proff
Toll-free: +1-888-778-7886 (USA/Canada)
International: +1-347-960-6455
Email: enquiry@pharmaproff.com
Web: https://www.pharmaproff.com
About Us:
Pharma Proff, is a frontline market intelligence and consulting solutions provider catering to the information and data needs of burgeoning sectors across the world, including pharmaceutical and healthcare. With meticulously curated research reports on the industry landscape, we empower companies in the healthcare and pharmaceutical sectors to make informed business decisions and base their marketing strategies with astuteness.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage
to this press release on woodPRI. woodPRI disclaims liability for any content contained in
this release.
Recommend
/newsMicroencapsulation Market Deep Analysis on Key Players - Dow Corning, Encapsys, Syngenta Crop Protection, Evonik Industries, 3M and Bayer
Market Study Report Adds Global Microencapsulation Market Size, Status and Forecast 2024 added to its database. The report provides key statistics on the current state of the industry and other analytical data to understand the market.
Extensive research is required for choosing the appropriate cor...
/newsGermany Airbag Market Size 2023: Global Share, Industry And Report Analysis By 2030 | Hyundai Mobis Co., Ltd. Key Safety Systems, Inc. Robert Bosch GmbH
Germany airbag market is expected to grow at a CAGR of around 6% during the forecast period. Germany Airbag Market research report refers to gathering and analyzing significant market data serve as best medium for various industry players to launch novel product or service. It is vital for key firms...
/newsSecurities Brokerages And Stock Exchanges Market Outlook 2021: Big Things are Happening
A new intelligence report released by HTF MI with title "Global Securities Brokerages And Stock Exchanges Market Survey & Outlook" is designed covering micro level of analysis by Insurers and key business segments, offerings and sales channels. The Global Securities Brokerages And Stock Exchange...
/newsRenewable Chemicals Market Emerging Trends and Competitive Landscape Forecast to 2028
The renewable chemicals market was valued at US$ 80,566.30 million in 2021 and is projected to reach US$ 1,76,750.76 million by 2028 it is expected to grow at a CAGR of 11.9% from 2021 to 2028. The research report focuses on the current market trends, opportunities, future potential of the market, a...
/newsHow Coronavirus is Impacting Cold Brew Coffee, Global Market Volume Analysis, Size, Share and Key Trends 2020-2026
"Market Latest Research Report 2020:
Los Angles United States, February 2020: The Cold Brew Coffee market has been garnering remarkable momentum in the recent years. The steadily escalating demand due to improving purchasing power is projected to bode well for the global market. QY Research's lates...
/newsCorporate E-Learning Market - Global Industry Size, Share, Key Players Analysis that are Infor, SkillSoft Corporation, Adrenna, CERTPOINT Systems and others with Regional Forecast to 2022
Overview:
E-Learning is used to enhance the learning procedures for newer job requirements and to make employees sound about the internal and external changes in the market and respective organizations. This method has created considerable differences in the ways of training and developing employee...
